Is Renal Artery Stenting Still Relevant? A Cohort Analysis
|
|
- Emily Montgomery
- 6 years ago
- Views:
Transcription
1 Is Renal Artery Stenting Still Relevant? A Cohort Analysis Sunil Naik, MD*, Brijesh Patel, DO, Anas Souqiyyeh, MD, Marc Zughaib, David Eastes, MPH, Marcel Zughaib, MD Abstract Atherosclerotic renal artery stenosis (ARAS) is a process that can lead to a decrease in renal perfusion pressure with subsequent activation of the renin-angiotensin-aldosterone system. The potential deleterious effects of renal function, uncontrolled hypertension and elevated levels of angiotensin II serve as the stimulus for pursuing renal artery stenting as a therapeutic option. The results from the previous studies have led to equivocal results and skepticism about this treatment modality. This is a retrospective cohort analysis of patients with uncontrolled blood pressure and severe renal artery lesions that underwent renal artery stenting from with up to 18 month follow up. Systolic and diastolic blood pressure showed a mean post-stenting reduction of 34 mmhg (p<0.05) and 13 mmhg (p<0.05) respectively. Renal function and the number of antihypertensive agents did not show a statistically significant difference. Appropriate patient and lesion selection with experienced operators can improve blood pressure reduction in patients with significant renovascular hypertension. Keywords Renovascular artery stenosis, Atherosclerotic renal artery stenosis, Renovascular hypertension, Cite this article as: Sunil Naik S, Patel B, Souqiyyeh A, Zughaib M, Eastes D, Zughaib M. Is Renal Artery Stenting Still Relevant? A Cohort Analysis. JCvD 2015;3(2): R I. INTRODUCTION enovascular hypertension caused by renal artery stenosis is a disease process with two distinct etiologies. Atherosclerotic renal artery stenosis (ARAS) and fibromuscular dysplasia (FMD) both cause renal artery stenosis and have vastly different treatment modalities. The beaded, aneurysmal appearance of FMD is best treated with balloon angioplasty and medical therapy while the therapeutic options [1, 2] for ARAS remain unresolved. Atherosclerotic disease of the renal arteries can lead to significant stenosis and a decrease in renal perfusion pressure. The subsequent activation of the renin-angiotensin aldosterone Received on 11 February No conflict of interest declared. From: Providence Hospital, Cardiology Department: Heart institute West Nine Mile Road. Southfield, Michigan, USA. *Corresponding Author - Sunil.Naik@providence-stjohnhealth.org system (RAAS) and increase in plasma angiotensin II has several deleterious effects. Sodium retention, vasoconstriction, generation of reactive oxygen species, production of aldosterone, sympathetic nerve activity, intrarenal prostaglandin concentration and cardiac/vascular remodeling are among the most common. [3-5] Significant ARAS has three well recognized systemic complications: resistant renovascular hypertension, renal ischemia and flash pulmonary edema. [6] A review of published reports that evaluated progression of atherosclerotic disease to complete occlusion of the renal artery found that the primary determinant was initial stenosis. [7] Thus, multiple therapeutic modalities have been explored to treat this condition including medical therapy, surgical revascularization and percutaneous intervention. In this study, our goal was to examine whether renal artery intervention in appropriately selected patients and performed by experienced operators is a viable and clinically useful strategy for the treatment of renovascular hypertension. Patients with uncontrolled blood pressure on two or more agents with significant renal artery stenosis of 70%, in whom secondary causes of hypertension had been ruled out, were targeted in this study. We performed a retrospective evaluation of 65 patients who underwent renal artery intervention. Blood pressure, number of antihypertensive agents and renal function were studied at particular time intervals. The study population is from a tertiary care, moderate sized hospital with a busy endovascular program between 2007 and II. METHODS Study Design: This study is a retrospective, single center, cohort analysis performed at Providence Hospital in Southfield, Michigan, USA. It was funded by the research department at our institution and approved by the institutional review board at Providence Hospital. Members of the writing committee take responsibility of the accuracy, interpretation and completeness of the data and integrity of this manuscript. Patients were searched in the Horizon Cardiology reporting system at Providence Hospital from 2007 to The query was performed using the words renal + visceral + PTA in order to encompass all possible renal artery interventions. All charts and angiographic data were analyzed individually to determine inclusion in the study. The predetermined exclusion criteria included stenoses < 70%, angioplasty alone, end stage renal disease on hemodialysis, inadequate baseline blood pressure recordings and visceral interventions not involving the renal 320
2 arteries. The severity of renal stenosis was evaluated angiographically by an operator, but reviewed before including the patient in the study by an interventional cardiologist and cardiology fellow. The baseline demographics and characteristics were collected and adjusted to rule out any confounding variables. Blood pressure, renal function, medications and comorbid conditions were collected at baseline and follow-up intervals of discharge, 0-6 months and 6-18 months. These were obtained from the Providence Hospital electronic medical record as well as records from two separate outpatient clinics where many of these patients followed up. The goal of this study was to determine the effectiveness of renal artery stenting in appropriately selected patients with severe uncontrolled hypertension on multiple medications. These patients all had significant ARAS of one or both renal arteries. This unique cohort was followed to show the true effectiveness of this seemingly controversial intervention. Statistical Analysis: The statistical tests performed were the paired t-test and the Wilson-cox sign test. Data was analyzed using the following methods for matched pairs presenting data with normal distribution. The paired t-test was used to test the likelihood Table 1: Baseline patient characteristics Baseline Characteristics Treated lesions (N) Treated Patients (n) Mean Age Race Caucasians African Americans Asian Unknown Sex Value % 22% 2% 8% Female 65% Male 35% No. of Medications* 2.8 Past medical history DM 37% CVA 8% PAD 52% CAD 78% Smokers 46% Renal Artery Stenosis 70-79% 25% 80-89% 51% >90% 22% Stenosis Side Right 40% Left 58% Creatinine Levelψ 1.3 mg/dl BP (mm Hg) Systolic Diastolic 172 ±7 83 ±4 DM=Diabetes, CVA=Cerebrovascular accident, PAD=Peripheral artery disease, CAD=Coronary artery disease. *The number of medications before the procedure was performed and averaged across 53 lesions where data was available. Past medical history relevant to hypertension risk and reported as percentage of the whole patients used. Percentage stenosis of the artery was divided into three categories 70-79, 80-89, and >90%. Side of stenosis. ψ Serum creatinine levels averaged from all patients used. that the mean values were statistically different from one another. For data sets where the distribution of points presented as non-normal, the Wilson-cox sign test was used with a 95% confidence interval and a power of 80%. Necessary sample size was calculated using a power of 80% and confidence of 95%. All calculations were conducted using STATA 12.1 [8]. Endpoints: The primary endpoints for this study included change in mean systolic and diastolic blood pressure at predetermined intervals. Blood pressure was recorded prior to the procedure, at discharge, 0-6 months and 6-18 months. Variable follow up times in this retrospective study required the use of intervals for analysis. Secondary endpoints included the number of antihypertensive medications and renal function. These data points were evaluated prior to the procedure and at the time intervals assigned above. The operators were allowed to adjust medications at their discretion. Treatment complications and serious adverse events were also reported in the results. III. RESULTS During this study of 70 lesions and 65 patients, 3 patients died of non-procedure related causes. They were analyzed with data and follow up information available prior to their death. The average age of the cohort was 73 years. Nearly 60% of all patients were female, and 62% were Caucasian. Baseline characteristics are detailed in Table 1 and indicated that 37% were diabetics, 8% had a history of cerebrovascular accident, 78% had coronary artery disease, 52% had peripheral artery disease, and 46% were smokers. On average, they were taking 2.80 anti-hypertensive medications of any class at baseline. The majority of lesions were 80-89% stenosed (~ 51%). The left and right renal artery involvement was 58% and 42%, respectively. The average systolic and diastolic blood pressures (n=65) at baseline were 172 mmhg (CI 95%, 164 to 179), and 83 mmhg (CI 95%, 78 to 87) (Table 2). We defined follow-up periods as discharge, (0 to 6 months), and (6 to 18 months). There were missing data on 18% (12 patients), 28% (18 patients) and 26% (17 patients) for each follow up period, respectively. Rather than comparing them to the cohort s average, we compared the patients mean SBP and DBP using paired t-test or Wilson-cox to their baseline pressure for each follow up interval so the cohorts served as their own control. 321
3 Table 2: Post-intervention follow up trends Post intervention data Severity of Renal Artery Follow up Trend data: mean BP (mm Hg), medications and creatinine Pre-procedure At Discharge 0-6 mo mo. SBP from the baseline (mm Hg) 172 ±7 142 ±5* 143 ±6* 138 ±6* 70-79% 164 ± ±7* 142 ±14* 138 ±11* 80-89% 170 ± ±8* 142 ±9* 137 ±8* >90% 183 ± ±9* 147 ±11* 147 ±9* DBP from the baseline (mm Hg) 83 ±4 70 ±3* 71 ±3* 70 ±4* 70-79% 77 ±9 66 ±7* 72 ±6* 74 ±8* 80-89% 85 ±6 71 ±5* 70 ±5* 68 ±4* >90% 84 ±6 71 ±4* 71 ±8* 73 ±12* Number of Medications 2.8 (n=55) 3.10 (n=53) 2.88 (n=34) 2.88 (n=33) Creatinine 1.30 (±0.14) 1.18 (±0.13)* 1.3 (±0.28) 1.2 (± 0.24) Complications *All averages were statistically significant from the pre-procedure Blood pressure calculated at confidence intervals of 95% corresponding to p value of Data were analyzed for the patients at each time interval and significant statistical differences were noted for each. At discharge, a total of 56 lesions were analyzed. The blood pressure measurements were SBP of 142 mmhg (CI 95%, 137 to 147 mmhg; p<0.05) and DBP of 70 mmhg (CI 95%, 67 to 73, p<0.05). Similarly, a total of 45 and 48 lesions were analyzed for (0 to 6 month), and (6 to 18 month) intervals, respectively. The mean SBP and DBP during the 0 to 6 month period were 143 mmhg (CI 95%, 137 to 146 mmhg; p<0.05) and 71 mmhg (CI 95%, 68 to 74; p<0.05). The (6 to 18 month) interval had mean SBP and DBP of 138 mmhg (CI 95%, 132 to 144 mmhg; p<0.05) and 70 mmhg (CI 95%, 66 to 74 mmhg; p<0.05). All reductions in blood pressure throughout the follow up intervals were statistically significant after the intervention (figure 1-2). The severity of stenosis marked by percentage and ranged from (70%-79%), (80%-89%) and (>90%) had a similar reduction trend post procedure for both systolic and diastolic blood pressure per time interval (Figure 3-4). The number of antihypertensive agents was also evaluated. At baseline a mean of 2.8 agents were used. This changed from 2.8 to 3.1, 2.88 and 2.88 at the aforementioned follow up intervals (table 2). This trend showed no difference in the mean number of antihypertensives in this cohort throughout the study. Similarly, renal function was measured using mean creatinine for each follow up interval period. Data showed a baseline mean creatinine value of 1.3. Subsequent levels were 1.18, 1.3 and 1.2 respectively for each follow up endpoint (Table 3). The p value for the 6-18 month time point was 0.24, but strong statistical conclusions are difficult to draw secondary to a small number of appropriate lab follow up. However, a trend from the available data suggested that there was no significant difference in renal function from pre-procedure to 6-18 months of follow-up. When we analyzed patients with co-morbid conditions, we found that the patients who did not have diabetes, coronary artery disease and/or peripheral artery disease have greater reduction in SBP from the baseline compared to the patients with these co-morbidities. These findings were based on trends in the data, but statistical analysis was not feasible secondary to small numbers for subgroup study (Table 3). IV. DISCUSSION Conclusive statements on the treatment of ARAS are lacking. Surgical revascularization has been performed in the past with improvement in renal function and blood pressure; however, this was associated with high procedural morbidity and mortality. The mortality associated with all renal reconstruction and renal bypasses was 5.5% and 5.2% respectively in a 1999 Table 3: Subgroup analysis post renal artery intervention. Follow-up BP post procedure per-time interval group analysis (mm Hg) Pre-procedure BP (mm Hg) (± MR) At Discharge 0-6 mo mo. Risk factor Total n* SBP DBP SBP DBP SBP DBP SBP DBP DM Present ±9 80 ±6 145 ±8 67 ± ±35 70 ± ±27 68 ±14 Absent ±7 86 ±5 140 ±17 72 ±8 136 ±27 72 ± ±22 72 ±11 CAD Present ±13 83 ±7 142 ±8 70 ±4 144 ±10 72 ±5 139 ±9 70 ±5 Absent ±13 83 ± ±10 71 ± ±23 68 ± ±16 76 ±16 PAD Present ±13 82 ±7 141 ±8 69 ±4 143 ±9 71 ±4 137 ±11 69 ±6 Absent ±16 86 ±9 144 ±6 72 ±6 145 ±14 72 ±8 141 ±11 72 ±7 Smoking Present ±20 82 ± ±8 71 ±6 139 ±9 71 ±5 134 ±7 66 ±5 Absent ±8 85 ±6 143 ±6 69 ±4 150 ±10 72 ±6) 144 ±11 75 ±7 CVA Present ±29 87 ± ±13 71 ± ±20 84 ± ±27 73 ±17 Absent ±13 83 ±7 141 ±9 70 ±5 143 ±10 70 ±5 139 ±11 70 ±6 DM=Diabetes, CVA=Cerebrovascular accident, PAD=Peripheral artery disease, CAD=Coronary artery disease, MR=Margin of Error. Figure 4: Diastolic blood pressure trend for all patients treated, for *Total (n) refers to 65 patients used. patient with 70-79%, 80-89%, and >90% initial stenosis at baseline and at discharge up to 18 months follow up. Calculated at p<
4 crossover rates, low patient numbers, intervention on [3, 4, 10] non-critical lesions and balloon angioplasty alone. These short-comings have resulted in skepticism in the medical community regarding this treatment modality. We feel that these circumstances have led to reluctance in adopting percutaneous stenting of the renal arteries as a viable and effective treatment modality for uncontrolled hypertension in this patient population. Figure 1: A comparison of baseline systolic blood pressure at baseline to three post procedure intervals (At discharge, by 6 months and by 18 months) calculated at p<0.05. The intent of this study was to evaluate the effect of renal artery stenting on a select cohort of patients with significant stenosis 70% and uncontrolled hypertension on at least two antihypertensive medications. The primary endpoint of mean blood pressure showed a statistically significant reduction at all 3 follow up time intervals up to 18 months. This illustrates the efficacy of renal artery stenting as well as its durability. The marked reduction in systolic blood pressure at discharge, 0-6 months and 6-18 months time intervals was 30, 25 and 29mmHg respectively (figure 1). This level of blood pressure reduction is not matched by any currently available single agent Figure 2: A comparison of baseline Diastolic blood pressure at baseline to three post procedure intervals (AT Discharge, by 6 months and by 18 months) calculated at p<0.05. article reviewing 600 operations. [9] Three of the major trials evaluating medical therapy and percutaneous intervention are DRASTIC, STAR, and ASTRAL. [3, 4, 10] Unfortunately, these studies remained inconclusive because of small sample size, treatment of hemodynamically insignificant stenoses, and high crossover rates. In the DRASTIC trial and a number of other studies in the early 1990 s, it was consistently noted that angioplasty alone had a high rate of procedural failures, complications, and restenosis. Subsequently, ASTRAL utilized PTA and stenting to improve these outcomes, but high crossover rates and treatment of insignificant stenoses led to equivocal results. [10] In a recently published trial, CORAL, demonstrated that systolic blood pressure was modestly decreased in stent group vs. medical therapy group and lasted throughout the follow-up period, though it showed that there was no benefit in preventing clinical event. [11] This trend was observed in our study. The treatment of renovascular hypertension and atherosclerotic renal artery stenosis with percutaneous interventions has been controversial, despite a reasonable patho-physiologic justification for it. Negative trials in the past have been inconclusive because of the high Figure 3: Systolic blood pressure trend for all patients treated, for patient with 70-79%, 80-89%, and >90% initial stenosis at baseline and at discharge up to 18 months follow up. Calculated at p<0.05. drug therapy. The results of our study are consistent with a recently published positive study, the HERCULES trial. [12] In the latter study, appropriately selected patients with significant stenosis 60% and uncontrolled blood pressure were included. A reduction of 17mmHg was noted out to 9 months of follow up. This well designed positive study reiterates the importance of patient selection as a primary determinant of therapeutic effectiveness of renal artery stenting. [12] Statistical evaluation of the secondary endpoint of renal function was compromised due to a lack of data in this retrospective cohort analysis and varying practice patterns of the physicians. However, the absolute mean creatinine at each interval showed no statistically significant change in renal function from the analysis that was performed. Despite improving renal perfusion, the overall kidney function did not improve. This may be due to distal embolization during the procedure and progressive renal parenchymal disease in 323
5 patients with multiple comorbidities. The benefit of distal embolic protection devices has been studied in a small trial. [13] A retrospective study showed no difference in GFR but a consistent reduction in blood pressure. [14] Conversely, another study showed improvement in GFR at 6 weeks post intervention. [13] These inconsistencies have reduced the use of distal embolic protection in renal artery interventions as a standard practice. Difficulty in placing these devices and having a sufficient landing zone are also some of the obstacles faced when using embolic protection devices. These devices were not used in any of our patients in the study. The number of antihypertensive agents was also analyzed and showed no reduction throughout the study period despite improvement in blood pressure control. One explanation may be that despite the substantial improvement in blood pressure, the subjects were not always at goal. Thus, providers may not have been inclined to reduce medical therapy despite better control. Finally, during subgroup analysis it was found that a greater reduction in blood pressure was noted in patients without coronary artery disease (CAD) than those with it. The number of patients in our study without CAD was only nine, thus a statistical analysis was not feasible but a trend was noted. We think that it could indicate the primary etiology of hypertension in patients without CAD is truly renal hypoperfusion and activation of the RAAS. Endovascular treatment of the lesion led to dramatic results in this situation. V. CONCLUSIONS Renal artery stenting is a viable option in the treatment of uncontrolled renovascular hypertension in appropriately selected patients with truly significant lesions. The marked and long-term improvement in hypertension seen in our study is consistent with other positive renal stenting trials performed. [12, 15] There is no clear evidence of improved renal function or a reduction in the number of antihypertensive agents with this intervention. The results of this study suggest that further investigation with large randomized controlled trials is needed to help determine the efficacy of percutaneous intervention for appropriately selected patients with renovascular atherosclerosis. These studies should compare current evidence-based optimal medical therapy to intervention performed on the appropriate patient cohort by experienced operators. The major limitation of this study was the retrospective cohort design. This design resulted in a non-standardized approach to medical therapy during the study period and inconsistencies in follow up. Evaluation of renal function and medication titration was left up to the operators making complete data collection difficult. Secondly, the single center experience results in a potential bias of a small number of operators who performed these procedures. Finally, evaluation for restenosis with Doppler or repeat angiography was not performed and would require a prospective design to appropriately assess this issue. REFERENCES [1.] Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJand Lumsden AB. The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia. Journal of vascular surgery 2008;48: [2.] Olin JWand Sealove BA. Diagnosis, management, and future developments of fibromuscular dysplasia. Journal of vascular surgery 2011;53: e1. [3.] Van Jaarsveld B, Krijnen P, Bartelink A, Dees A, Derkx F, Man in't Veld Aand Schalekamp M. The Dutch Renal Artery Stenosis Intervention Cooperative (DRASTIC) Study: rationale, design and inclusion data. Journal of hypertension supplement; official journal of the international society of hypertension 1998;16:S21-7. [4.] Bax L, Mali WP, Buskens E, Koomans HA, Beutler JJ, Braam B, Beek FJ, Rabelink TJ, Postma CT, Huysmans FT, Deinum J, Thien T, Schultze Kool LJ, Woittiez AJ, Kouwenberg JJ, van den Meiracker AH, Pattynama PM, van de Ven PJ, Vroegindeweij D, Doorenbos CJ, Aarts JC, Kroon AA, de Leeuw PW, de Haan MW, van Engelshoven JM, Rutten MJ, van Montfrans GA, Reekers JA, Plouin PF, La Batide Alanore A, Azizi M, Raynaud A, Harden PN, Cowling Mand Group SS. The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. Journal of nephrology 2003;16: [5.] Libby Pand Braunwald E. Braunwald's heart disease : a textbook of cardiovascular medicine. In. 8th ed. Philadelphia: Saunders/Elsevier; 2008; [6.] Safian RD and Textor SC. Renal-artery stenosis. The new england journal of medicine 2001;344: [7.] Mwipatayi BP, Beningfield SJ, White LE, Irish A, Abbas Mand Sieunarine K. A review of the current treatment of renal artery stenosis. European journal of vascular and endovascular surgery; The official journal of the european society of vascular surgery 2005;29: [8.] Statacorp. Stata Statistical Software: Release 12. College Station, TX; StataCorp LP. [9.] Darling RC, Kreienberg PB, Chang BB, Paty PS, Lloyd WE, Leather RP and Shah DM. Outcome of renal artery reconstruction: analysis of 687 procedures. Annals of surgery 1999;230:524-30; [10.] Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson Aand Scoble J. Revascularization versus medical therapy for renal-artery stenosis. The new england journal of medicine 2009;361: [11.] Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB, Sr., Dworkin LD and Investigators C. Stenting and medical therapy for atherosclerotic renal-artery stenosis. Then new england journal of medicine 2014;370: [12.] Jaff MR, Bates M, Sullivan T, Popma J, Gao X, Zaugg M, Verta Pand Investigators H. Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial. Catheterization and cardiovascular interventions; Official journal of the society for cardiac angiography & interventions 2012;80: [13.] Edwards MS, Craven BL, Stafford J, Craven TE, Sauve KJ, Ayerdi J, Geary RLand Hansen KJ. Distal embolic protection during renal artery angioplasty and stenting. Journal of vascular surgery 2006;44: [14.] Singer GM, Setaro JF, Curtis JPand Remetz MS. Distal embolic protection during renal artery stenting: impact on hypertensive patients with renal dysfunction. Journal of clinical hypertension 2008;10: [15.] Lederman RJ, Mendelsohn FO, Santos R, Phillips HR, Stack RSand Crowley JJ. Primary renal artery stenting: characteristics and outcomes after 363 procedures. American heart journal 2001;142:
Renal Artery Stenosis: Insights from the CORAL Trial
Renal Artery Stenosis: Insights from the CORAL Trial Christopher J. Cooper, M.D., FACC, FACP Dean and Senior Vice President University of Toledo, College of Medicine President, Ohio Chapter ACC State of
More informationDisclosure of Potential Conflicts. Renal Artery Stenosis. RAS Epidemiology. Road Map. Background. ASDIN 7th Annual Scientific Meeting
Renal Artery Stenosis Disclosure of Potential Conflicts Cytopherx, Inc. R4 Vascular, Inc. Bard Peripheral Vascular Spectranetics, Inc. Alexander S. Yevzlin, MD Associate Professor of Medicine (CHS) ASDIN
More informationRAS Epidemiology. Renal Artery Stenosis. Pathophysiology of RAS. Disclosure of Potential Conflicts. Background Pathophysiology of RAS.
Renal Artery Stenosis RAS Epidemiology Common Disease Incidence General Population 0.1% Hypertensive Population 4% HTN & Suspected CAD 10-20% Malignant HTN 20-30% Malignant HTN and CKD 30-40% Alexander
More informationCase yr old lady; type 2 Diabetes 10 yrs; PVD; hypertension
Does this patient have flash pulmonary oedema? Philip A Kalra Professor of Nephrology, Salford Royal Hospital and University of Manchester, UK 73 yr old lady; type 2 Diabetes 1 yrs; PVD; hypertension Acute
More informationCurrent Role of Renal Artery Stenting in Patients with Renal Artery Stenosis
Current Role of Renal Artery Stenting in Patients with Renal Artery Stenosis Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea Etiology Fibromuscular
More informationLife After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention
Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis
More informationAtherosclerotic Renovascular Hypertension : Lessons from Recent Clinical Studies
Review ISSN 1738-5997 (Print) ISSN 2092-9935 (Online) Electrolyte Blood Press 8:87-91, 2010 doi: 10.5049/EBP.2010.8.2.87 Atherosclerotic Renovascular Hypertension : Lessons from Recent Clinical Studies
More informationEndovascular treatment
210..217 NEPHROLOGY 2010; 15, S210 S217 doi:10.1111/j.1440-1797.2009.01243.x Endovascular treatment Date written: February 2009nep_1243 Final submission: August 2009 Authors: Robert MacGinley, Subramanian
More informationCoral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.
Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.. Dr. Javier Ruiz Aburto, FACS, FICS Assistant Professor Ponce School of Medicine Puerto Rico
More informationRenal Artery Stenting Associated With Improvement in Renal Function and Blood Pressure Control in Long-Term Follow-Up
2016 The Author(s). 2016 Published The Author(s) by S. Karger AG, Basel www.karger.com/kbr Published by S. Karger AG, Basel 278 1423-0143/16/0413-0278$39.50/0 Accepted: February 08, 2016 www.karger.com/kbr
More informationMichael Meuse, M.D. Vascular and Interventional Radiology
Michael Meuse, M.D. Vascular and Interventional Radiology Which patient would likely benefit from renal artery revascularization? Patient A- 60 y/o male with 20 year hx of htn; on 2 drug therapy for 10
More informationA Closer Look: Renal Artery Stenosis. Renal artery stenosis (RAS) is defined as a TOPICS FROM CHEP. Shawn s stenosis
TOPICS FROM CHEP A Closer Look: Renal Artery Stenosis On behalf of the Canadian Hypertension Education Program (CHEP), Dr. Tobe gives an overview of renal artery stenosis, including the prevalence, screening
More informationCORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective
CORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective Michael R. Jaff, DO Massachusetts General Hospital Boston, Massachusetts, USA Michael R. Jaff, DO Conflicts of Interest
More informationEffective Health Care
Number 5 Effective Health Care Comparative Effectiveness of Management Strategies for Renal Artery Stenosis Executive Summary Background Renal artery stenosis (RAS) is defined as the narrowing of the lumen
More informationRenal Artery Stenting
Renal Artery Stenting J.P. Reilly, MD, FSCAI Ochsner Medical Center Speaker s bureau: Astra Zeneca and Lilly/Diachi Sankyo Prevalence of RAS is high in cath population. Renal artery intervention can help
More informationPercutaneous renal artery stent implantation in the treatment of atherosclerotic renal artery stenosis
EXPERIMENTAL AND THERAPEUTIC MEDICINE Percutaneous renal artery stent implantation in the treatment of atherosclerotic renal artery stenosis YOUBIN HU 1*, YONGGUANG ZHANG 1*, HUA WANG 2, YONG YIN 2, CHUNHUA
More informationRenal artery stenosis
Renal artery stenosis Dr. Alexander Woywodt Consultant Renal Physician, Royal Preston Hospital Preston, 31.10.2007 Menu anatomy of the renal arteries diseases of the large renal arteries atherosclerotic
More informationPCI for Renal Artery stenosis
PCI for Renal Artery stenosis Why should we treat Renal Artery Stenosis? Natural History of RAS RAS is progressive disease Study Follow-up (months) Pts Progression N (%) Total occlusion Wollenweber Meaney
More informationAngioplasty with stent in renal artery stenosis: our experience
Rev Chil Radiol 2016; 22(1): 13-19. Angioplasty with stent in renal artery stenosis: our experience Johanna Marcela Vasquez Veloza *, José Luis Abades Vázquez, José Luis Cordero Castro. Interventional
More informationUrgent Renal Artery Stenting as Successful Treatment of Rapidly Progressive Anuric Renal Artery Stenosis in a Single-Kidney Patient
Proceedings of UCLA Healthcare -VOLUME 20 (2016)- CLINICAL VIGNETTE Urgent Renal Artery Stenting as Successful Treatment of Rapidly Progressive Anuric Renal Artery Stenosis in a Single-Kidney Patient Shanon
More informationRenal Intervention. Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014
Renal Intervention Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014 Disclosure Information Douglas E. Drachman, MD, FACC Abbott Vascular, Inc.: Advisory
More informationAtherosclerotic renal artery stenosis (RAS) is a common. Original Articles
Original Articles Validity of Estimated Glomerular Filtration Rates for Assessment of Baseline and Serial Renal Function in Patients With Atherosclerotic Renal Artery Stenosis Implications for Clinical
More informationControversies in the management of the renal artery stenosis
REVIEW ARTICLE Cardiology Journal 2013, Vol. 20, No. 1, pp. 11 16 10.5603/CJ.2013.0003 Copyright 2013 Via Medica ISSN 1897 5593 Controversies in the management of the renal artery stenosis Khalil Kanjwal
More informationFibromuscular Dysplasia (FMD) of the renal arteries Angiographic features and therapeutic options
Fibromuscular Dysplasia (FMD) of the renal arteries Angiographic features and therapeutic options Poster No.: C-0630 Congress: ECR 2012 Type: Educational Exhibit Authors: K. I. Ringe, B. Meyer, F. Wacker,
More informationRENAL ARTERY PTA. JH PEREGRIN IKEM, Prague
RENAL ARTERY PTA JH PEREGRIN IKEM, Prague PTRA/Stenting PTRA technical success rate > 90 % In some patients helps control hypertension In some patients can improve kidney function Serious complications
More informationKEY WORDS: Bilateral Renal Artery Stenosis, Cardiac Catherization, Incidental Findings, Associated Co- morbidity
BILATERAL RENAL ARTERY STENOSIS - AN INCIDENTAL FINDING DURING CARDIAC CATHETERIZATION Review of 15 Cases of BRAS Stenting at Queen Alia Heart Institute in Jordan Hatem Hamdan Salaheen Abbadi 1 ABSTRACT:
More informationPERIPHERAL VASCULAR DISEASE. Original Studies
PERIPHERAL VASCULAR DISEASE Original Studies Catheterization and Cardiovascular Interventions 80:343 350 (2012) Significant Reduction in Systolic Blood Pressure Following Renal Artery Stenting in Patients
More informationOriginal Studies. Catheterization and Cardiovascular Interventions 00: (2012)
Catheterization and Cardiovascular Interventions 00:000 000 (2012) Original Studies Significant Reduction in Systolic Blood Pressure Following Renal Artery Stenting in Patients With Uncontrolled Hypertension:
More informationRenal Artery Stenting With Embolic Protection
Renal Artery Stenting With Embolic Protection Embolic protection during renal stenting may be beneficial, but new device designs are necessary. BY RAJESH M. DAVE, MD Renal artery stenosis (RAS) is the
More informationMEET /06/2013 SESSION : RENAL AND VISCERAL
MEET 2003 11/06/2013 SESSION : RENAL AND VISCERAL AFTER 35 YEARS, WHAT ARE THE INDICATIONS AND RESULTS OF PTRA IN PATIENTS WITH RI OR RVH? THOMAS SOS, MD NYPH CORNELL New York, NY THOMAS SOS, MD NYPH CORNELL
More information11 TH ANNUAL VASCULAR NONINVASIVE TESTING SYMPOSIUM NOVEMBER 10, 2018
11 TH ANNUAL VASCULAR NONINVASIVE TESTING SYMPOSIUM NOVEMBER 10, 2018 RENAL ARTERY DISEASE AND RENOVASCULAR HYPERTENSION 1 WHAT IS RENOVASCULAR HYPERTENSION? https://my.clevelandclinic.org/health/diseases/16459-renovascular-hypertension
More informationCatheter-Based Renal Denervation (RDN)
Hypertension lecture 3: Catheter-Based Renal Denervation (RDN) Adapted from slides prepared by Dr IOEBRAHIM, UNITAS HOSPITAL and others Hypertension Epidemiology 30% Untreated 35% Treated & Controlled
More informationClaudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study Authors: Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DC, Reynolds MR, Lewis BA, Cerezo J, Oldenburg
More informationFibromuscular dysplasia a rare cause of renovascular hypertension Case study and overview of the literature data
, pp.316 320 Fibromuscular dysplasia a rare cause of renovascular hypertension Case study and overview of the literature data Geavlete O*, Călin C*, Croitoru M*, Lupescu I**, Ginghină C* *Cardiology Department,
More informationThe role of percutaneous revascularization for renal artery stenosis
The role of percutaneous revascularization for renal artery stenosis Gregory J Dubel and Timothy P Murphy Abstract: Renal artery stenosis (RAS) is usually caused by atherosclerosis or fibromuscular dysplasia.
More informationOutcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting
Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting Xue F Y, Bettmann M A, Langdon D R, Wivell W A Record Status
More informationEpidemiologic and clinical comparison of renal artery stenosis in black patients and white patients
ORIGINAL ARTICLES Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients Andrew C. Novick, MD, Safwat Zald, MD, David Goldfarb, MD, and Ernest E. Hodge, MD,
More informationDuplex Ultrasound of the Renal Arteries. Duplex Ultrasound. In the Beginning
Duplex Ultrasound of the Renal Arteries DIMENSIONS IN HEART AND VASCULAR CARE 2013 PENN STATE HEART AND VASCULAR INSTITUTE ROBERT G. ATNIP MD PROFESSOR OF SURGERY AND RADIOLOGY Duplex Ultrasound Developed
More informationTreatment of renal artery in-stent restenosis with sirolimus-eluting stents
Treatment of renal artery in-stent restenosis with sirolimus-eluting stents Vascular Medicine 15(1) 3 7 The Author(s) 2009 Reprints and permission: http://www. sagepub.co.uk/journalspermission.nav DOI:
More informationRenal Artery FFR. Woo-Young Chung. Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center
Renal Artery FFR Woo-Young Chung Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center Why renal FFR? Renal artery angioplasty (PTRA) Indication of Renal artery angioplasty
More informationMasahiko Fujihara, MD
Verify the efficacy of renal artery stenting to define the predictive factors by physiological assessment with pressure wire gradient VERDICT study Masahiko Fujihara, MD Kishiwada Tokushukai Hospital Osaka,
More informationRevascularization versus Medical Therapy for Renal-Artery Stenosis
The new england journal of medicine original article versus Medical Therapy for Renal-Artery Stenosis The ASTRAL Investigators* Abstract Background Percutaneous revascularization of the renal arteries
More informationRenal Artery Disease. None > 65,000,000. Learning objectives: Renal Artery Disease
Renal Artery Disease Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Financial Disclosure Information Renal Artery Disease Robert McBane, MD None To appreciate: Learning objectives:
More informationPeripheral Arterial Disease: Who has it and what to do about it?
Peripheral Arterial Disease: Who has it and what to do about it? Seth Krauss, M.D. Alaska Annual Nurse Practitioner Conference September 16, 2011 Scope of the Problem Incidence: 20%
More informationRenal artery stenosis, defined as a narrowing
IN THE LITERATURE Is There Any Reason to Stent Atherosclerotic Renal Artery Stenosis? Commentary on ASTRAL Investigators. Revascularization versus medical therapy for renal artery stenosis. N Engl J Med.
More informationOriginal paper. Introduction. treatment of atherosclerotic RAS is controversial. Percutaneous
Original paper Clinical outcomes and effectiveness of renal artery stenting in patients with critical atherosclerotic renal artery stenosis: does it improve blood control and renal function assessed by
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationNatural history and progression of atherosclerotic renal vascular stenosis
204..209 NEPHROLOGY 2010; 15, S204 S209 doi:10.1111/j.1440-1797.2009.01242.x Natural history and progression of atherosclerotic renal vascular stenosis Date written: December 2008nep_1242 Final submission:
More informationAtherosclerotic renovascular disease
Cardiology 69 Atherosclerotic renal artery stenosis Atherosclerotic renal artery stenosis is largely a disease of the elderly and is commonly associated with hypertension and renal dysfunction. Blood pressure
More informationLong-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
Mochida et al. Renal Replacement Therapy (2018) 4:5 DOI 10.1186/s41100-018-0147-x RESEARCH Open Access Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous
More informationRENAL ARTERY STENOSIS. Grand Rounds 10/11/2011
RENAL ARTERY STENOSIS Grand Rounds 10/11/2011 ARAS Prevalence- 0.5% overall population, 5.5% in ckd pts No correlation between ischemic nephropathy and severity of stenosis Increased risk of vascular events-
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationRenal artery revascularization: Outcomes stratified by indication for intervention
Renal artery revascularization: Outcomes stratified by indication for intervention Virendra I. Patel, MD, Mark F. Conrad, MD, Christopher J. Kwolek, MD, Glenn M. LaMuraglia, MD, Thomas K. Chung, MS, and
More informationChronic Mesenteric Ischemia
Chronic Mesenteric Ischemia February 10 th, 2018 Moses Kim, MD Vascular Surgery Iowa Heart and Vascular Financial Disclosures Employee-Iowa Heart Center/Mercy-Des Moines Case 75 yo male who presented
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationShould Mesenteric Revascularization Be Staged: Report of 3 Cases One With Reperfusion Hemorrhage
Should Mesenteric Revascularization Be Staged: Report of 3 Cases One With Reperfusion Hemorrhage Ayhan Olcay MD 1, Kivanc Yalin MD 1, Sukriye Ebru Golcuk MD 1, Sukru Sanli MD 2 1. Bayrampasa Kolan Hospital,
More informationAtherosclerotic renal artery stenosis and reconstruction
http://www.kidney-international.org & 2006 International Society of Nephrology mini review Atherosclerotic renal artery stenosis and reconstruction B Krumme 1 and J Donauer 2 1 Deutsche Klinik für Diagnostik,
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationRenal artery stenosis is the most common cause of secondary hypertension. Over 90% of renal
General cardiology ARTERIOSCLEROTIC RENAL ARTERY STENOSIS: CONSERVATIVE VERSUS INTERVENTIONAL MANAGEMENT c RENAL Additional references appear on the Heart website Correspondence to: Priv. Doz. Dr C Haller,
More informationAppropriate Patient Identification For Renal Artery Intervention Remains Challenging
Renal Intervention Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM Director, Interventional Cardiology, Cardiovascular Institute Director, Cardiac Cath Labs, Rhode Island &The Miriam Hospitals None Disclosures
More informationThe European Consensus on Fibromuscular Dysplasia
The European Consensus on Fibromuscular Dysplasia Alexandre Persu, M.D.-PhD Cardiology Department Cliniques Universitaires Saint-Luc Catholic University of Louvain Brussels, Belgium Eur J Clin Invest.
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationIncidence and Prevalence of Atherosclerotic Renal Artery Stenosis (RAS) in Patients with Coronary Artery Disease (CAD)
Incidence and Prevalence of Atherosclerotic Renal Artery Stenosis (RAS) in Patients with Coronary Artery Disease (CAD) AHMW Islam, S Munwar, S Talukder, AQM Reza Dept. of Invasive & Interventional Cardiology,
More informationBlood Pressure Treatment in 2018
Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
More informationFibromuscular dysplasia (FMD) encompasses a heterogeneous
Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia A Systematic Review and Meta-Analysis Ludovic Trinquart, Claire Mounier-Vehier, Marc Sapoval, Nathalie Gagnon,
More informationComparative Effectiveness Review (Update) Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: 2007 Update
This report is based on research conducted by the Tufts-New England Medical Center Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville,
More informationRenal Artery Diameter: A New Parameter Beyond an Old Disease The Renal Artery Stenosis
Renal Artery Diameter: A New Parameter Beyond an Old Disease The Renal Artery Stenosis Luca Zanoli, Stefania Rastelli Department of Medical and Pediatric Sciences University of Catania, Catania, Italy
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationThe diagnosis of curable, secondary causes of hypertension
Hypertension Grand Rounds Telling Tails Very High Plasma Renin Levels Prompt the Diagnosis of Renal Artery Stenosis, Despite Initial Negative Imaging Michele Petruzzelli, Kevin P. Taylor, Brendan Koo,
More informationOstial Stents and Distal Embolic Protection During Renal Stenting
Ostial Stents and Distal Embolic Protection During Renal Stenting John R. Laird, MD Professor of Medicine Director of the Vascular Center UC Davis Medical Center Limitations of Current Techniques of Renal
More informationVascular Imaging Original Research
MDCT Angiography of Renal Arteries Vascular Imaging Original Research Adam D. Talenfeld 1 Ryan B. Schwope Huntley J. Alper Emil I. Cohen Robert A. Lookstein Talenfeld AD, Schwope RB, Alper HJ, Cohen EI,
More informationLEFT MAIN DISEASE PATIENT PROFILE
LEFT MAIN DISEASE PATIENT PROFILE MUHAMMAD YOUSUF SHAIKH*, MANSOOR AHMAD*, A RASHEED*, DAD M. JAN*, MANSOOR ALI* Background: Left main coronary artery (LMCA) disease is a potentially lethal disease that
More informationResearch Article Abdominal Aortic Aneurysms and Coronary Artery Disease in a Small Country with High Cardiovascular Burden
ISRN Cardiology, Article ID 825461, 4 pages http://dx.doi.org/10.1155/2014/825461 Research Article Abdominal Aortic Aneurysms and Coronary Artery Disease in a Small Country with High Cardiovascular Burden
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationPreoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry
More informationORIGINAL ARTICLE. Department of Nephrology, Endocrinology and Metabolic Diseases, Silesian Medical University, Katowice, Poland
ORIGINAL ARTICLE Cardiology Journal 2009, Vol. 16, No. 6, pp. 514 520 Copyright 2009 Via Medica ISSN 1897 5593 Comparison of early and late efficacy of percutaneous transluminal renal angioplasty with
More informationRenal Artery Stenting
Renal Artery Stenting We are unable to predict patients who will benefit from RAS MEET 2008 Thomas Ischinger MD FACC FESC Heart Center Bogenhausen Munich, Germany Disclosure Statement of Financial Interest
More informationNew Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008
New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants
More informationSecondary Hypertension: A Real World Approach
Secondary Hypertension: A Real World Approach Evan Brittain, MD December 7, 2012 Kingston, Jamaica Disclosures None Real World Causes Renovascular Hypertension Endocrine Obstructive Sleep Apnea Pseudosecondary
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationRenal PEI: critical appraisal
Renal PEI: critical appraisal On Topaz M.D., F.A.C.C.,F.S.V.M. Professor of Medicine & Pathology Director, Interventional Cardiology McGuire Veterans Medical Center Virginia Commonwealth University Richmond,
More informationTreating Hypertension from
Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System
More informationReal World Experience with Renal Denervation Therapy
JCR 2013 Real World Experience with Renal Denervation Therapy Seung-Hyuk Choi Division of Cardiology Samsung Medical Center Seoul, Korea Hypertension A Major Public Health Burden Astonishing prevalence
More informationI-Hui Wu, M.D. Ph.D. Clinical Assistant Professor Cardiovascular Surgical Department National Taiwan University Hospital
Comparisons of Aortic Remodeling and Outcomes after Endovascular Repair of Acute and Chronic Complicated Type B Aortic Dissections I-Hui Wu, M.D. Ph.D. Clinical Assistant Professor Cardiovascular Surgical
More informationPeripheral Vascular Disease
Peripheral artery disease (PAD) results from the buildup of plaque (atherosclerosis) in the arteries of the legs. For people with PAD, symptoms may be mild, requiring no treatment except modification of
More informationAtherosclerotic renovascular disease in United States patients. aged 67 years or older: Risk factors, revascularization, and prognosis.
Kidney International, Vol. 8 (2005), pp. 2 01 Atherosclerotic renovascular disease in United States patients aged 7 years or older: Risk factors, revascularization, and prognosis PHILIP A. KALRA, HAIFENG
More informationUltrasound of the Renal Arteries
Ultrasound of the Renal Arteries Greg Curry Vascular Ultrasound Workshop Aug 2017 The Examination Technique Pathophysiology Role of US then and now Background Live Scanning Ultrasound Population: 20% Hypertensive
More informationSplit Renal Function Outcome after Renal Angioplasty in Patients with Unilateral Renal Artery Stenosis
J Am Soc Nephrol 12: 1235 1241, 2001 Split Renal Function Outcome after Renal Angioplasty in Patients with Unilateral Renal Artery Stenosis AGNÈS LA BATIDE-ALANORE,* MICHEL AZIZI, MARC FROISSART, ALAIN
More informationArterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial
Early reports Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial Peter J G van de Ven, Robert Kaatee, Jaap J Beutler, Frederick J A Beek, Arend-Jan
More informationImmediate Normalisation of Blood Pressure following Intervention in Functional Total Occlusion of Unilateral Renal Artery with an Atrophic Kidney
Immediate Normalisation of Blood Pressure following Intervention in Functional Total Occlusion of Unilateral Renal Artery with an Atrophic Kidney Dr Parminder Singh Otaal Assistant Professor Department
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationRenal artery stenosis (RAS) is a widely recognized
The Renal Stenting Downturn Why are we stenting less? By George V. Moukarbel, MD, and Mark W. Burket, MD Renal artery stenosis (RAS) is a widely recognized cause of secondary hypertension, renal dysfunction,
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationNOT FOR PUBLICATION, QUOTATION, OR CITATION RESOLUTION NO. 22
BE IT RESOLVED, Sponsored By: RESOLUTION NO. 22 that the American College of Radiology adopt the ACR SIR Practice Parameter for the Performance of Angiography, Angioplasty, and Stenting for the Diagnosis
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationHybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case
Hybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case Chernyavskiy M.,MD,PhD, Chernova D., Zherdev N., Chernov A. Almazov National Medical Research Centre, St.Petersburg, Russia
More informationDiagnosis of Renal Artery Stenosis (RAS)
May 2001 Diagnosis of Renal Artery Stenosis (RAS) Kurt Fink, Harvard Medical School, Year III Epidemiology Hypertension -Affects 60 million Americans Essential HTN >95% of cases Secondary HTN 1-5% of cases
More information